Amiodarone hydrochloride is a class III antiarrhythmic drug prescribed commonly for atrial fibrillation and ventricular arrhythmias. It has several clinically important toxic effects, including pneumonitis, hepatotoxicity, thyroid dysfunction, and corneal microdeposits with visual disturbances.
1-3 The initial experience with this drug also suggested substantial potential for neurologic toxic effects, with frequencies in these early reports ranging from 27.5% to as high as 74%
1,2,4-6; the most common of these neurologic adverse effects have been tremor, ataxia, and peripheral neuropathy. However, various other neurologic adverse effects have also been reported, including cognitive impairment/encephalopathy,
4,6,7 parkinsonism,
8,9 optic neuropathy,
10 and myopathy.
6,11 On the other hand, the frequency of neurologic adverse effects in longer-term amiodarone clinical trials has been much lower, at less than 5%.
12-15